LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

ADMA Biologics Inc

Închisă

SectorSănătate

19.68 2.5

Rezumat

Modificarea prețului

24h

Curent

Minim

19.14

Maxim

19.9

Indicatori cheie

By Trading Economics

Venit

-85M

27M

Vânzări

-2.7M

115M

P/E

Medie Sector

24.244

56.602

EPS

0.136

Marjă de profit

23.435

Angajați

685

EBITDA

-4.7M

35M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+59.74% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.1B

4.9B

Deschiderea anterioară

17.18

Închiderea anterioară

19.68

Sentimentul știrilor

By Acuity

50%

50%

177 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

ADMA Biologics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 apr. 2025, 14:13 UTC

Principalele dinamici ale pieței

ADMA Biologics Shares Hit 52-Week High After FDA Approval

Comparație

Modificare preț

ADMA Biologics Inc Așteptări

Obiectiv de preț

By TipRanks

59.74% sus

Prognoză pe 12 luni

Medie 30.67 USD  59.74%

Maxim 35 USD

Minim 25 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruADMA Biologics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 23.5406Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

177 / 382 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.